<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04464473</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000532</org_study_id>
    <secondary_id>R01MH121509</secondary_id>
    <nct_id>NCT04464473</nct_id>
  </id_info>
  <brief_title>cTBS/fMRI Study of Hierarchical Control in the PFC</brief_title>
  <official_title>cTBS/fMRI Study of Hierarchical Control in the PFC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to examine the effect of transcranial magnetic stimulation&#xD;
      (TMS) on the prefrontal cortex and posterior parietal cortex.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Comprehensive Control Task (CCT) was designed to examine hierarchical control in a&#xD;
      single, well-controlled factorial task. On each trial, participants view a letter surrounded&#xD;
      by a colored shape at a particular screen location. Color cues the relevant feature, letter&#xD;
      or location, for a block of trials. The first trial of a block requires a decision of whether&#xD;
      the stimulus is the first position of a circular sequence (sequence start). Subsequent trials&#xD;
      require a decision of whether the viewed stimulus follows the previous stimulus in a circular&#xD;
      sequence (sequence 1-back). The letter sequence (C-O-M-I-C) and spatial sequence (Top&#xD;
      Left-Top Right-Bottom Left-Bottom Right-Top Left) are difficulty-matched.&#xD;
&#xD;
      Shape cues the task to perform. Squares indicate the standard baseline task, and each block&#xD;
      begins and ends with baseline trials. Different shapes indicate sub-tasks. In Switching&#xD;
      blocks, shape-switches (e.g. from square to circle or circle to square) cue the sequence&#xD;
      start task. Shape-repeats cue the sequence 1-back task. In Planning blocks, triangle shapes&#xD;
      indicate that the stimulus can be ignored (automatic &quot;no&quot; response). All the while, the last&#xD;
      square-shaped stimulus must be retained as a reference for the next square-shaped stimulus.&#xD;
      Finally, in Dual blocks, diamond shapes indicate switching (sequence start) and also&#xD;
      planning. The reversion back to square shapes requires sequence matching to the distal,&#xD;
      previous square.&#xD;
&#xD;
      The design is factorial with stimulus-domain x contextual control x temporal control&#xD;
      orthogonally manipulated. Full details of the CCT have been previous described in Nee &amp;&#xD;
      D'Esposito, 2016; 2017.&#xD;
&#xD;
      The focus in this study will be comparison of FPl-TMS, MFG-TMS, and S1-TMS in an interleaved&#xD;
      fMRI-TMS-fMRI design. The logic is to test the apical status of the FPl/MFG through the&#xD;
      extent to which TMS impacts other PFC areas and behavior.&#xD;
&#xD;
      Each experiment will begin with 1 session of the CCT with fMRI to localize PFC targets. Each&#xD;
      participant will then perform 3 counter-balanced sessions wherein a different site will be&#xD;
      targeted by TMS followed immediately by fMRI on the CCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFC-PPC effective connectivity</measure>
    <time_frame>baseline, pre-intervention and immediately after intervention</time_frame>
    <description>effective connectivity among areas of the prefrontal and posterior parietal cortex in the blood oxygenation level dependent (BOLD) signal assessed with functional magnetic resonance imaging (fMRI) [note, this measure has no units]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFC-PPC activation</measure>
    <time_frame>baseline, pre-intervention and immediately after intervention</time_frame>
    <description>blood oxygenation level dependent (BOLD) signal in areas of the prefrontal and posterior parietal cortex assessed with functional magnetic resonance imaging (fMRI) [note, this measure has no units]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>temporal control performance</measure>
    <time_frame>baseline, pre-intervention and immediately after intervention</time_frame>
    <description>behavioral performance (reaction time in milliseconds, and percent correct) on conditions involving temporal control in the comprehensive control task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contextual control performance</measure>
    <time_frame>baseline, pre-intervention and immediately after intervention</time_frame>
    <description>behavioral performance (reaction time in milliseconds, and percent correct) on conditions involving contextual control in the comprehensive control task</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Transcranial Magnetic Stimulation</condition>
  <arm_group>
    <arm_group_label>FPl-TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MFG-TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-TMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcranial magnetic stimulation to primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial magnetic stimulation</intervention_name>
    <description>Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.</description>
    <arm_group_label>FPl-TMS</arm_group_label>
    <arm_group_label>MFG-TMS</arm_group_label>
    <arm_group_label>S1-TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18 and 30&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Native English speaker or fluent by the age of 6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of psychiatric disorders&#xD;
&#xD;
          -  History of neurological disorders&#xD;
&#xD;
          -  Receiving medications for psychiatric or neurological disorders&#xD;
&#xD;
          -  Familial history of epilepsy&#xD;
&#xD;
          -  Taking any drugs or medications that are pro-epileptic&#xD;
&#xD;
          -  Metal anywhere in the head excluding the mouth&#xD;
&#xD;
          -  Tinnitus&#xD;
&#xD;
          -  Women who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek E Nee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriella T Vill, BA</last_name>
    <phone>850-645-4066</phone>
    <email>vill@psy.fsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida State University Psychology Department Building</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella T Vill, BA</last_name>
      <phone>850-645-4066</phone>
      <email>vill@psy.fsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSU MRI Facility</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alecia Lapointe, MA</last_name>
      <phone>850-644-1889</phone>
      <email>alecia.lapointe@med.fsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Florida State University</investigator_affiliation>
    <investigator_full_name>Derek Nee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Behavioral and imaging data will be shared</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within a year following publication of findings</ipd_time_frame>
    <ipd_access_criteria>Behavioral and imaging data will be accessible from https://nda.nih.gov/edit_collection.html?id=3448 by NDA users.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

